Equities

Fuji Pharma Co Ltd

Fuji Pharma Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,350.00
  • Today's Change25.00 / 1.89%
  • Shares traded138.90k
  • 1 Year change-7.53%
  • Beta0.7456
Data delayed at least 20 minutes, as of Nov 13 2024 02:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in JPY

The 2 analysts offering 12 month price targets for Fuji Pharma Co Ltd have a median target of 1,990.50, with a high estimate of 2,000.00 and a low estimate of 1,981.00. The median estimate represents a 50.23% increase from the last price of 1,325.00.
High50.9%2,000.00
Med50.2%1,990.50
Low49.5%1,981.00

Dividends in JPY

In 2023, Fuji Pharma Co Ltd reported a dividend of 37.00 JPY, which represents a 5.71% increase over last year. The 2 analysts covering the company expect dividends of 43.75 JPY for the upcoming fiscal year, an increase of 18.24%.
Div growth (TTM)5.71%
More ▼

Earnings history & estimates in JPY

Fuji Pharma Co Ltd reported annual 2024 earnings of 252.85 per share on Nov 12, 2024.
Average growth rate+41.02%
More ▼

Revenue history & estimates in JPY

Revenue forecasts are not available for Fuji Pharma Co., Ltd..
Average growth rate+1.27%
Fuji Pharma Co., Ltd. had revenues for the full year 2024 of 46.14m. This was 12.84% above the prior year's results.
Average growth rate+8.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.